Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ACA Ruling Is Double Whammy For PrEP Coverage, With Contraception And Vaccines Still At Risk

Executive Summary

 Obamacare’s affordable access to HIV pre-exposure prophylaxis is jeopardized by court order. Access to vaccines, contraception may also be at risk as the case continues to play out in higher courts. 

You may also be interested in...



Medicaid Coverage For PrEP Without Restrictions, Cost Sharing Backed By President’s Budget

Legislation could facilitate faster access without cost sharing or restrictions for new HIV pre-exposure prophylaxis. The White House said its budget proposal to expand Medicare price negotiation would save $160bn more than the Inflation Reduction Act's existing negotiation provisions.

Washington gears up for next SCOTUS Obamacare fight

Washington is gearing up for the next big US Supreme Court fight over the Affordable Care Act (ACA) – a law that was enacted nearly five years ago and has had at least two major decisions come down from the justices since 2012.

GSK Makes New Adult Immunization Push, Seeks Reimbursement Changes Following RSV Approvals

From ACIP to Part D to data transparency, GSK has several policy asks as it prepares to launch its new RSV vaccine for older adults. The Pink Sheet spoke with GSK’s vaccine policy lead about the firm’s new data platform and the worrisome US vaccination trends following the Covid pandemic.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS147988

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel